Germany
· Delayed Price · Currency is EUR Zelira Therapeutics Company Description
Zelira Therapeutics Limited, a biopharmaceutical company, engages in the research, development, and commercialization of cannabinoid-based medicines for the treatment of various medical conditions in Australia and the United States.
It offers formulations under the HOPE brand in Australia, Washington, Pennsylvania, and Louisiana, as well as develops ZENIVOL, a cannabinoid drug for the treatment of chronic insomnia.
The company also provides over the counter (OTC) products, including SprinJeneCBD, an oral care product; and acne treatment products under the RAF FIVE name, as well as Zyraydi, an enhanced distillate capture and dissolution matrix technology.
In addition, it offers products for autism and chronic noncancer pain. The company was formerly known as Zelda Therapeutics Limited and changed its name to Zelira Therapeutics Limited in December 2019.
Zelira Therapeutics Limited was incorporated in 2003 and is based in Perth, Australia.
| Country | Australia |
| Founded | 2003 |
| Industry | Pharmaceutical Preparations |
| CEO | Oludare Odumosu |
Contact Details
Address: 101 St Georges Terrace Perth, 6000 Australia | |
| Phone | 61 8 6558 0886 |
| Website | zeliratx.com |
Stock Details
| Ticker Symbol | G1G |
| Exchange | Frankfurt Stock Exchange |
| Fiscal Year | July - June |
| Reporting Currency | AUD |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Oludare Odumosu | Chief Executive Officer |
| Rahul Ganesan | Chief Financial Officer |